These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29722200)

  • 1. Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy.
    Tang M; Horsley P; Lewis CR
    Intern Med J; 2018 May; 48(5):583-587. PubMed ID: 29722200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.
    Waks AG; Tolaney SM; Galar A; Arnaout A; Porter JB; Marty FM; Winer EP; Hammond SP; Baden LR
    Breast Cancer Res Treat; 2015 Nov; 154(2):359-67. PubMed ID: 26420402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
    Krzyzanowska MK; Julian JA; Powis M; Howell D; Earle CC; Enright KA; Mittmann N; Trudeau ME; Grunfeld E
    BMC Cancer; 2019 Sep; 19(1):884. PubMed ID: 31488084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    Huszno J; Budryk M; Kołosza Z; Nowara E
    Oncology; 2013; 85(5):278-82. PubMed ID: 24217135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.
    Krzyzanowska MK; Julian JA; Gu CS; Powis M; Li Q; Enright K; Howell D; Earle CC; Gandhi S; Rask S; Brezden-Masley C; Dent S; Hajra L; Freeman O; Spadafora S; Hamm C; Califaretti N; Trudeau M; Levine MN; Amir E; Bordeleau L; Chiarotto JA; Elser C; Husain J; Laferriere N; Rahim Y; Robinson AG; Vandenberg T; Grunfeld E
    BMJ; 2021 Dec; 375():e066588. PubMed ID: 34880055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study.
    Ishikawa T; Sakamaki K; Narui K; Kaise H; Tsugawa K; Ichikawa Y; Mukai H;
    Jpn J Clin Oncol; 2016 Jul; 46(7):692-5. PubMed ID: 27162322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
    Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of health-care services during chemotherapy for breast cancer.
    Baena-Cañada JM; Estalella-Mendoza S; Rosado-Varela P; Expósito-Álvarez I; González-Guerrero M; Díaz-Blanco MC; Cortés-Carmona C; Ramírez-Daffós P; Arriola-Arellano E; Rueda-Ramos A; Solana-Grimaldi L; Benítez-Rodríguez E
    Eur J Cancer; 2012 Dec; 48(18):3328-34. PubMed ID: 22683169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
    Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
    Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis.
    Bowen ME; Mone MC; Buys SS; Sheng X; Nelson EW
    Ann Surg; 2017 Mar; 265(3):448-456. PubMed ID: 27280515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
    van den Berg MMGA; Kok DE; Posthuma L; Kamps L; Kelfkens CS; Buist N; Geenen M; Haringhuizen A; Heijns JB; van Lieshout RHMA; Los M; Sommeijer DW; Timmer-Bonte JNH; de Kruif ATCM; van Laarhoven HWM; Kampman E; Winkels RM
    Breast Cancer Res Treat; 2019 Jan; 173(2):475-481. PubMed ID: 30353244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ; Chambers J; Mcauley F; Kaplan T; Letourneau J; Hwang J; Kim MO; Melisko ME; Rugo HS; Esserman LJ; Rosen MP
    Breast Cancer Res Treat; 2017 Aug; 165(1):151-159. PubMed ID: 28503722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
    Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
    Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
    Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients.
    Specht MC; Miller CL; Skolny MN; Jammallo LS; O'Toole J; Horick N; Isakoff SJ; Smith BL; Taghian AG
    Ann Surg Oncol; 2013 Sep; 20(9):2835-41. PubMed ID: 23689935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.